Skip to main content

Clinical Data Buys Back Xmark Warrants, Retires Debt

NEW YORK, Jan. 17 (GenomeWeb News) - Clinical Data has bought back a total of 130,000 warrants from Xmark Opportunity Fund for total cash consideration of $130,000, the company said today. Each repurchased warrant carried the right to buy Clinical Data common stock at a price of $28.50 per share.


The repurchase opportunity was the result of the diagnostic company's retiring a $4.5 million dollar note previously issued to Xmark, said Clinical Data chief financial officer Mark Shooman in a statement.


The warrants and the debt were assumed by Clinical datae in its October 2005, $56 million all-stock purchase of Genaissance.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.